In 403 people aged 6+ in South Africa with rifampicin-resistant pulmonary TB, a 6-month bedaquiline, linezolid, delamanid regimen was noninferior to 9-month standard care: success 86.1% vs 86.0% (risk difference −0.2 points). Grade ≥3 adverse events 31.2% vs 37.0%.
RCTn = 403
Conradie et al. A Pragmatic Trial of a 6-Month Strategy for Rifampicin-Resistant Tuberculosis